721 related articles for article (PubMed ID: 33217955)
1. The Angiopoietin-2 and TIE Pathway as a Therapeutic Target for Enhancing Antiangiogenic Therapy and Immunotherapy in Patients with Advanced Cancer.
Leong A; Kim M
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33217955
[TBL] [Abstract][Full Text] [Related]
2. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy.
Gerald D; Chintharlapalli S; Augustin HG; Benjamin LE
Cancer Res; 2013 Mar; 73(6):1649-57. PubMed ID: 23467610
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic and Antitumor Activity of BI 836880, a Dual Vascular Endothelial Growth Factor and Angiopoietin 2 Inhibitor, Alone and Combined with Programmed Cell Death Protein-1 Inhibition.
Hofmann I; Baum A; Hofmann MH; Trapani F; Reichel-Voda C; Ehrensperger D; Aichinger M; Ebner F; Budano N; Schweifer N; Sykora M; Depla E; Boucneau J; Gschwind A; Kraut N; Hilberg F; Künkele KP
J Pharmacol Exp Ther; 2023 Mar; 384(3):331-342. PubMed ID: 36241203
[TBL] [Abstract][Full Text] [Related]
4. Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer.
Khan KA; Wu FT; Cruz-Munoz W; Kerbel RS
EMBO Mol Med; 2021 Jul; 13(7):e08253. PubMed ID: 34125494
[TBL] [Abstract][Full Text] [Related]
5. Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges.
Li SJ; Chen JX; Sun ZJ
Cancer Commun (Lond); 2021 Sep; 41(9):830-850. PubMed ID: 34137513
[TBL] [Abstract][Full Text] [Related]
6. [Tumor angiogenesis: new approaches to cancer therapy].
Marmé D
Onkologie; 2001 Feb; 24 Suppl 1():1-5. PubMed ID: 11441305
[TBL] [Abstract][Full Text] [Related]
7. Angiopoietin-2: development of inhibitors for cancer therapy.
Hu B; Cheng SY
Curr Oncol Rep; 2009 Mar; 11(2):111-6. PubMed ID: 19216842
[TBL] [Abstract][Full Text] [Related]
8. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
[TBL] [Abstract][Full Text] [Related]
9. Soluble Tie2 overrides the heightened invasion induced by anti-angiogenesis therapies in gliomas.
Cortes-Santiago N; Hossain MB; Gabrusiewicz K; Fan X; Gumin J; Marini FC; Alonso MM; Lang F; Yung WK; Fueyo J; Gomez-Manzano C
Oncotarget; 2016 Mar; 7(13):16146-57. PubMed ID: 26910374
[TBL] [Abstract][Full Text] [Related]
10. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges.
Fukumura D; Kloepper J; Amoozgar Z; Duda DG; Jain RK
Nat Rev Clin Oncol; 2018 May; 15(5):325-340. PubMed ID: 29508855
[TBL] [Abstract][Full Text] [Related]
11. Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.
Kashyap AS; Schmittnaegel M; Rigamonti N; Pais-Ferreira D; Mueller P; Buchi M; Ooi CH; Kreuzaler M; Hirschmann P; Guichard A; Rieder N; Bill R; Herting F; Kienast Y; Dirnhofer S; Klein C; Hoves S; Ries CH; Corse E; De Palma M; Zippelius A
Proc Natl Acad Sci U S A; 2020 Jan; 117(1):541-551. PubMed ID: 31889004
[TBL] [Abstract][Full Text] [Related]
12. Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference.
Biel NM; Siemann DW
Cancer Lett; 2016 Oct; 380(2):525-533. PubMed ID: 25312939
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin AT(1) and AT(2) receptors differentially regulate angiopoietin-2 and vascular endothelial growth factor expression and angiogenesis by modulating heparin binding-epidermal growth factor (EGF)-mediated EGF receptor transactivation.
Fujiyama S; Matsubara H; Nozawa Y; Maruyama K; Mori Y; Tsutsumi Y; Masaki H; Uchiyama Y; Koyama Y; Nose A; Iba O; Tateishi E; Ogata N; Jyo N; Higashiyama S; Iwasaka T
Circ Res; 2001 Jan; 88(1):22-9. PubMed ID: 11139469
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic therapy in malignant glioma: promise and challenge.
Sathornsumetee S; Rich JN
Curr Pharm Des; 2007; 13(35):3545-58. PubMed ID: 18220791
[TBL] [Abstract][Full Text] [Related]
15. The complex role of angiopoietin-2 in the angiopoietin-tie signaling pathway.
Thurston G; Daly C
Cold Spring Harb Perspect Med; 2012 Sep; 2(9):a006550. PubMed ID: 22951441
[TBL] [Abstract][Full Text] [Related]
16. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition.
Daly C; Eichten A; Castanaro C; Pasnikowski E; Adler A; Lalani AS; Papadopoulos N; Kyle AH; Minchinton AI; Yancopoulos GD; Thurston G
Cancer Res; 2013 Jan; 73(1):108-18. PubMed ID: 23149917
[TBL] [Abstract][Full Text] [Related]
17. Specifically targeting angiopoietin-2 inhibits angiogenesis, Tie2-expressing monocyte infiltration, and tumor growth.
Huang H; Lai JY; Do J; Liu D; Li L; Del Rosario J; Doppalapudi VR; Pirie-Shepherd S; Levin N; Bradshaw C; Woodnutt G; Lappe R; Bhat A
Clin Cancer Res; 2011 Mar; 17(5):1001-11. PubMed ID: 21233403
[TBL] [Abstract][Full Text] [Related]
18. Multitargeting strategy using lenvatinib and golvatinib: maximizing anti-angiogenesis activity in a preclinical cancer model.
Nakazawa Y; Kawano S; Matsui J; Funahashi Y; Tohyama O; Muto H; Nakagawa T; Matsushima T
Cancer Sci; 2015 Feb; 106(2):201-7. PubMed ID: 25458359
[TBL] [Abstract][Full Text] [Related]
19. Utilizing combinatorial engineering to develop Tie2 targeting antagonistic angiopoetin-2 ligands as candidates for anti-angiogenesis therapy.
Shlamkovich T; Aharon L; Barton WA; Papo N
Oncotarget; 2017 May; 8(20):33571-33585. PubMed ID: 28422724
[TBL] [Abstract][Full Text] [Related]
20. Role of Angiopoietin-2 in Vascular Physiology and Pathophysiology.
Akwii RG; Sajib MS; Zahra FT; Mikelis CM
Cells; 2019 May; 8(5):. PubMed ID: 31108880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
